PCI Biotech announced that results from preclinical studies on tuberculosis performed in collaboration with The University of Zurich and ETH Zurich are accepted for publication in Frontiers in Immunology, a high impact immunology journal. The article title is 'Photochemically-mediated inflammation and cross-presentation of Mycobacterium bovis BCG proteins stimulates strong CD4 and CD8 T-cell responses in mice'.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.586 NOK | +2.32% | -7.79% | -24.30% |
1st Jan change | Capi. | |
---|---|---|
-24.30% | 5.26M | |
-3.46% | 102B | |
+1.41% | 96.29B | |
+2.13% | 22.18B | |
-15.84% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.65% | 16.36B | |
+4.39% | 13.97B | |
+31.35% | 12.17B |
- Stock Market
- Equities
- PCIB Stock
- News PCI Biotech Holding ASA
- PCI Biotech Announces Publication of Preclinical Tuberculosis Results